Join us on 12-15-2022 for a live seminar about RNA SEQ
We’ve grown from our original platform for human monoclonal antibody discovery, the ATX-Gx™, to support a spectrum of biologics. Discovery groups can find the best drug against their target and develop innovative new therapeutic formats.
We aggregate, improve, co-develop, and outlicense foundational precompetitive drug discovery platform technologies.
We provide services and capabilities to discover therapeutic drug candidates for our partners.
We collaborate to build new asset-focused companies leveraging this expertise and infrastructure.
We develop, improve, license, and share foundational, pre-competitive drug discovery platform technologies. We provide services and support to discover therapeutic drug candidates for our partners and the broader ecosystem. We collaborate to build new, asset-focused companies leveraging our expertise and infrastructure and support innovative ecosystem partners who share our mission.
We offer our technologies and capabilities to the entire drug discovery community—from academic scientists, small and medium biotech, to the largest biopharma—on affordable, non-exclusive terms. This network of drug discovery teams creates innovations and shares services that are widely available through collaboration to benefit all.
We reinvest 100% of our revenue into innovation and access to innovation to continually improve our offering for partners. Access our offerings through:
Join the over 130 companies already working one or more of Alloy’s technologies. We develop, improve, license, and share foundational, pre-competitive discovery platforms and offer broad access to the global drug discovery community, including other CROs who can support your drug discovery efforts. We have active research and collaborations across our six modalities and currently offer broad access to our first two modalities: Antibodies and TCRs.
If you need help beyond your current internal or CRO capabilities, we have built one of the world’s best discovery services team conducting dozens of high-touch, bespoke therapeutic discovery campaigns per year across Alloy’s 5 global research sites. We can work with you in a custom and fully integrated drug discovery approach that deploys our complete offering of proprietary in vivo, in vitro and in silico discovery platforms combined with advanced analytics, antigen generation, functional assay, informatics, and machine learning capabilities to discover the best therapeutic candidate against your target of interest.
We envision a future where all Big Pharma can access cutting-edge innovations in real-time and royalty-free to unlock the potential of internal drug discovery teams in all companies. Our best companies shouldn’t have to wait 20 years for patents to expire to get unfettered access to the newest pre-competitive platforms and technologies. Alloy’s Innovation Subscriptions give unlimited access to all our current and forthcoming technology, for a one-stop solution to your discovery challenges. Combined with our commitment to reinvesting 100% of our revenue back into innovation and access to innovation, this creates a powerful flywheel of innovation for all Innovation Subscription partners.
There is no one-size-fits-all engagement with Alloy. We partner flexibly and creatively across each collaboration, activating our stable of platform technologies, discovery services, and company creation capabilities to meet our partners’ goals.
We empower scientists by democratizing access to foundational tools, technologies, services, and company creation capabilities. We reduce barriers in drug discovery to help the best treatments get to patients—faster. May the best drug win.
Watch our mission video.
By design, our model is concierge and collaborative, just like our name. We will never have our own drug pipeline. We collaborate with our partners to leverage the full potential of our technology and services, as an innovation engine for the drug discovery industry. How can we help you reach your goals?
We are a team of 100+ people across 5 research sites, and our work is amplified by our ecosystem of hundreds of companies and thousands of engaged researchers.
We are a team of 75+ people across 5 research sites, and our work is amplified through our ecosystem of hundreds.
Explore:
Our research facilities:
Boston, MA
Cambridge, UK
Basel, CH
San Francisco, CA
Athens, GA
© 2023 Alloy Therapeutics, Inc. All Rights Reserved.